Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.

He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).

His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
203 entries « 1 of 21 »

Sénécal V, Barat C, Tremblay MJ

The delicate balance between neurotoxicity and neuroprotection in the context of HIV-1 infection.

Journal Article

Glia, 69 (2), 2021.

Abstract | Links:

Breton Y, Barat C, Tremblay MJ

The Balance between p53 Isoforms Modulates the Efficiency of HIV-1 Infection in Macrophages.

Journal Article

J Virol, 95 (20), 2021.

Abstract | Links:

Wessels JM, Nguyen PV, Vitali D, Mueller K, Vahedi F, Felker AM, Dupont HA, Bagri P, Verschoor CP, Deshiere A, Mazzulli T, Tremblay MJ, Ashkar AA, Kaushic C

Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice.

Journal Article

Sci Rep, 11 (1), 2021.

Abstract | Links:

Saba I, Barat C, Chabaud S, Reyjon N, Leclerc M, Jakubowska W, Orabi H, Lachhab A, Pelletier M, Tremblay MJ, Bolduc S

Immunocompetent Human 3D Organ-Specific Hormone-Responding Vaginal Mucosa Model of HIV-1 Infection.

Journal Article

Tissue Eng Part C Methods, 27 (3), 2021.

Abstract | Links:

Senecal V, Barat C, Gagnon MT, Vanasse F, Leboeuf M, Gosselin D, Tremblay MJ

Altered expression of fractalkine in HIV-1-infected astrocytes and consequences for the virus-related neurotoxicity.

Journal Article

J Neurovirol, 27 (2), 2021.

Abstract | Links:

Desrosiers V, Barat C, Breton Y, Ouellet M, Tremblay MJ

Thymidylate synthase is essential for efficient HIV-1 replication in macrophages.

Journal Article

Virology, 561 , 2021.

Abstract | Links:

Proust A, Barat C, Leboeuf M, Drouin J, Gagnon MT, Vanasse F, Tremblay MJ

HIV-1 infection and latency-reversing agents bryostatin-1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes.

Journal Article

Glia, 68 (11), 2020.

Abstract | Links:

Wessels JM, Lajoie J, Cooper MIJH, Omollo K, Felker AM, Vitali D, Dupont HA, Nguyen PV, Mueller K, Vahedi F, Kimani J, Oyugi J, Cheruiyot J, Mungai JN, Deshiere A, Tremblay MJ, Mazzulli T, Stearns JC, Ashkar AA, Fowke KR, Surette MG, Kaushic C

Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice.

Journal Article

Dis Model Mech, 12 (10), 2019.

Abstract | Links:

Nazli A, Dizzell S, Zahoor MA, Ferreira VH, Kafka J, Woods MW, Ouellet M, Ashkar AA, Tremblay MJ, Bowdish DM, Kaushic C

Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier.

Journal Article

Cell Mol Immunol, 16 (2), 2019.

Abstract | Links:

Breton Y, Desrosiers V, Ouellet M, Deshiere A, Torresilla C, Cohen EA, Tremblay MJ

Expression of MDM2 in Macrophages Promotes the Early Postentry Steps of HIV-1 Infection through Inhibition of p53.

Journal Article

J Virol, 93 (7), 2019.

Abstract | Links:

203 entries « 1 of 21 »
Signaler des ajouts ou des modifications

Active projects

  • Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and C04+ T-cells for HIV cure, from 2019-04-01 to 2024-03-31
  • Chaire du recherche du Canada en immuno-rétrovirologie humaine, from 2015-01-01 to 2021-12-31
  • Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2023-03-31
  • Microglia as a viral reservoir for HIV-1 in the human brain and its role in neuroinflammation, from 2021-04-01 to 2026-03-31

Recently finished projects

  • Centre de recherche sur les interactions hôte-parasite (CRIHP), from 2015-04-01 to 2021-03-31
  • Development of a safe, effective and clinically acceptable VSV-based HIV vaccine, from 2017-04-01 to 2020-03-31
  • Journée de la recherche de la Faculté de médecine, from 2010-11-24 to 2020-03-31
Data provided by the Université Laval research projects registery